이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - amiodarone hydrochloride - tablets - amiodarone hydrochloride 200 mg - amiodarone - coronary insufficiency, arrhythmias resistant to other treatments.

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - fluoxetine as hydrochloride - solution (oral) - fluoxetine as hydrochloride 4 mg/ml - fluoxetine - adults:major depressive episodes.obsessive-compulsive disorder (ocd).bulimia nervosa: fluoxetine is indicated as a complement of psychotherapy for the reduction of binge-eating and purging activity.children and adolescents aged 8 years and above:moderate to severe major depressive episode, if depression is unresponsive to psychological therapy after 4-6 sessions. antidepressant medication should be offered to a child or young person with moderate to severe depression only in combination with a concurrent psychological therapy.

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - film coated tablets - bisoprolol hemifumarate 1.25 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35%, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - bisoprolol fumarate - tablets - bisoprolol fumarate 10 mg - bisoprolol - management of angina pectoris, hypertention. treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - tablets - bisoprolol hemifumarate 2.5 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - bisoprolol fumarate - tablets - bisoprolol fumarate 5 mg - bisoprolol - management of angina pectoris, hypertention. treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

이스라엘 - 영어 - Ministry of Health

unipharm ltd, israel - roxithromycin - tablets - roxithromycin 150 mg - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.